{
    "organizations": [],
    "uuid": "4bc366a1ca8b977af254656d903b660542203dea",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sinovac-announces-preliminary-resu/brief-sinovac-announces-preliminary-results-of-phase-iii-trial-on-sipv-idUSASC09WIL",
    "ord_in_thread": 0,
    "title": "BRIEF-Sinovac Announces Preliminary Results Of Phase Iii Trial On Sipv",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19, 2018 / 1:22 PM / Updated 21 minutes ago BRIEF-Sinovac Announces Preliminary Results Of Phase Iii Trial On Sipv Reuters Staff \nApril 19 (Reuters) - Sinovac Biotech Ltd: \n* SINOVAC ANNOUNCES PRELIMINARY RESULTS OF PHASE III TRIAL ON SIPV \n* SINOVAC BIOTECH - PRELIM RESULTS OF TRIAL AFTER UNBLINDING SHOW SEROCONVERSION RATE OF POLIOVIRUS TYPE II IS SUPERIOR TO CONTROL VACCINE Source text for Eikon: Further company coverage:",
    "published": "2018-04-19T16:19:00.000+03:00",
    "crawled": "2018-04-19T16:49:26.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "preliminary",
        "result",
        "phase",
        "iii",
        "trial",
        "sipv",
        "reuters",
        "staff",
        "april",
        "reuters",
        "sinovac",
        "biotech",
        "ltd",
        "sinovac",
        "announces",
        "preliminary",
        "result",
        "phase",
        "iii",
        "trial",
        "sipv",
        "sinovac",
        "biotech",
        "prelim",
        "result",
        "trial",
        "unblinding",
        "show",
        "seroconversion",
        "rate",
        "poliovirus",
        "type",
        "ii",
        "superior",
        "control",
        "vaccine",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}